Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced a symposium presentation highlighting clinical data from an ...

Sana Biotechnology reports six-month results from a first-in-human study demonstrating safe pancreatic islet cell transplantation for type 1 diabetes without immunosuppression. Sana Biotechnology ...

Sana's first-in-human study shows HIP technology allows islet cells to avoid immune rejection and produce insulin without immunosuppression. Reliance on initial results: The press release heavily ...

CRANBURY, N.J.--(BUSINESS WIRE)--Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, today announced the dosing of the first patient ...

New research appearing in the journal Nature Biotechnology answers important questions about the viability of treatments that seek to replace diseased and aged cells in the central nervous system with ...

Explore the revolutionary potential of biotechnology and gene editing, alongside crucial ethical considerations and ...

ATHENS, Ga. & SAN JOSE, Calif.--(BUSINESS WIRE)--Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the ...

Scientists have developed Spudcell, an advanced synthetic cell capable of adapting to its environment and learning survival skills, marking a breakthrough in synthetic biology.

In RIT’s biotechnology bachelor’s degree you’ll develop technologies for genetics, agriculture, pharmaceuticals, vaccine development, energy/ environment, forensics, and more. Hands on Experience: ...

Biotechnology advances offer immense public health and consumer potential, but come with serious risks. A recent workshop held by the Council on Foreign Relations brought experts together to discuss ...

HudsonAlpha Institute's HOPE-AD study offers Alzheimer's risk assessment, revealing proactive steps high-risk individuals can ...

With the biotechnology and pharmaceutical industries reporting a record number of drugs in phase 3 clinical trials, a survey of US medical schools is critical of industry control over these trials.